

NOVO NORDISK A S  
Form 6-K  
January 02, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

December 18, 2017

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

\_\_\_\_\_

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

**Novo Nordisk A/S – Share repurchase programme**

**Bagsværd, Denmark, 18 December 2017** – On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 2 February 2017.

Under the programme initiated 1 November 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 4.8 billion in the period from 1 November 2017 to 30 January 2018.

Since the announcement as of 11 December 2017, the following transactions have been made under the programme:

|                                 | <b>Number of<br/>B shares</b> | <b>Average<br/>purchase price</b> | <b>Transaction<br/>value, DKK</b> |
|---------------------------------|-------------------------------|-----------------------------------|-----------------------------------|
| Accumulated, last announcement  | 7,320,000                     |                                   | 2,357,910,636                     |
| 11 December 2017                | 250,000                       | 329.44                            | 82,361,201                        |
| 12 December 2017                | 260,000                       | 333.13                            | 86,614,294                        |
| 13 December 2017                | 245,000                       | 337.09                            | 82,586,678                        |
| 14 December 2017                | 245,000                       | 336.45                            | 82,430,776                        |
| 15 December 2017                | 245,000                       | 328.40                            | 80,457,431                        |
| Accumulated under the programme | 8,565,000                     |                                   | 2,772,361,016                     |

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](http://novonordisk.com).

With the transactions stated above, Novo Nordisk owns a total of 54,556,054 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 2 February 2017. As of 15 December 2017, Novo Nordisk has repurchased a total of 53,456,831 B shares equal to a transaction value of DKK 14,972,332,044.

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube*

## **Further information**

### *Media:*

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com  
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com

### *Investors:*

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com  
Hanna Ögren +45 3079 8519 haoe@novonordisk.com  
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com  
Christina Kjær +45 3079 3009 cnje@novonordisk.com  
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

**Novo Nordisk A/S** Novo Allé Telephone:

Edgar Filing: NOVO NORDISK A S - Form 6-K

Investor Relations 2880 Bagsværd +45 4444 8888 Internet:  
Denmark www.novonordisk.com  
CVR no:

24 25 67 90

Company announcement No 93 / 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: December 18, 2017

Lars Fruergaard Jørgensen

Chief Executive Officer